Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients

NCT03149900 · clinicaltrials.gov ↗

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Psoriasis Vulgaris

Interventions

DRUG: Secukinumab

Sponsor

Diamant Thaci

Collaborators

[object Object]